Fox Run Management L.L.C. Sells 6,635 Shares of Keros Therapeutics, Inc. $KROS

Fox Run Management L.L.C. lowered its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 34.9% during the second quarter, Holdings Channel.com reports. The firm owned 12,354 shares of the company’s stock after selling 6,635 shares during the quarter. Fox Run Management L.L.C.’s holdings in Keros Therapeutics were worth $165,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Corebridge Financial Inc. lifted its position in shares of Keros Therapeutics by 6.4% during the first quarter. Corebridge Financial Inc. now owns 16,212 shares of the company’s stock valued at $165,000 after buying an additional 972 shares during the last quarter. CWM LLC lifted its position in Keros Therapeutics by 87.5% during the second quarter. CWM LLC now owns 5,000 shares of the company’s stock valued at $67,000 after acquiring an additional 2,333 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Keros Therapeutics by 15.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock valued at $227,000 after acquiring an additional 2,982 shares in the last quarter. Rhumbline Advisers grew its holdings in Keros Therapeutics by 9.3% in the first quarter. Rhumbline Advisers now owns 44,669 shares of the company’s stock worth $455,000 after purchasing an additional 3,802 shares during the last quarter. Finally, Rafferty Asset Management LLC increased its position in shares of Keros Therapeutics by 20.8% during the first quarter. Rafferty Asset Management LLC now owns 55,332 shares of the company’s stock worth $564,000 after purchasing an additional 9,531 shares in the last quarter. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Stock Down 0.2%

Keros Therapeutics stock opened at $17.26 on Friday. Keros Therapeutics, Inc. has a 52 week low of $9.12 and a 52 week high of $72.37. The company has a market capitalization of $525.91 million, a price-to-earnings ratio of 11.21, a price-to-earnings-growth ratio of 0.38 and a beta of 1.12. The stock has a 50-day moving average price of $15.66 and a 200 day moving average price of $14.73.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.93. Keros Therapeutics had a net margin of 26.12% and a return on equity of 9.51%. The company had revenue of $14.26 million for the quarter, compared to the consensus estimate of $4.22 million. During the same quarter in the prior year, the company earned ($1.41) EPS. Keros Therapeutics’s quarterly revenue was up 3585.6% on a year-over-year basis. Research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the business’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $84,975,125.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the firm’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $95,659,436.00. The SEC filing for this sale provides additional information. Insiders own 20.60% of the company’s stock.

Wall Street Analyst Weigh In

KROS has been the subject of a number of recent analyst reports. Zacks Research raised Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, November 7th. Wedbush raised their price target on Keros Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Wells Fargo & Company cut their price objective on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Keros Therapeutics in a research report on Wednesday, October 8th. Finally, Oppenheimer reissued an “outperform” rating and set a $27.00 target price (up previously from $23.00) on shares of Keros Therapeutics in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Keros Therapeutics currently has a consensus rating of “Hold” and an average target price of $30.22.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.